报价延迟最少15分钟:2026/10/18 19:15 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.42 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.86/-0.64
|
|
企业价值
113.47M
|
| 资产负债 |
|
每股账面净值
0.36
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
11.07M
|
|
每股收益
0.25
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune responseagainst tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms. |
